Phaseline

Companies › Shanghai Unicar-Therapy Bio-medicine Technology

Shanghai Unicar-Therapy Bio-medicine Technology: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ssCART-19
CAR-T cell therapy targeting CD19 on B-cell malignancies
CD19Phase 1B Cell LymphomaJan 2027
U32 CAR-T
CAR-T cell therapy
–Phase 1Acute Myeloid LeukaemiaDec 2027
U87 autologous CAR T-cell
anti-EGFR CAR-T cell therapy
–Phase 1Nasopharynx CancerDec 2027
U16
CAR-T cell therapy targeting CD19
–Phase 1Relapsed or Refractory Non-Hodgkin's LymphomaDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07093073ssCART-19Phase 1B Cell LymphomaOncologyJan 2027
NCT07036250U32 CAR-TPhase 1Acute Myeloid LeukaemiaOncologyDec 2027
NCT06614686U87 autologous CAR T-cellPhase 1Nasopharynx CancerOncologyDec 2027
NCT06987916ssCART-19Phase 1B Cell LymphomaOncologyApr 2028
NCT05768529U16Phase 1Relapsed or Refractory Non-Hodgkin's LymphomaOncologyDec 2028

Targets

CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.